Home > Insider Trading > Filing (0001209191-17-041954)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
816284	Celgene Corp	CELG	Pharmaceutical Preparations (2834)	222711928

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1276550	J James Loughlin	C/O Celgene Corporation 86 Morris Avenue Summit NJ 07901		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-06-26	9,250	$24.97	32,877	No	4	M	Direct
Common Stock	Disposition	2017-06-26	9,250	$133.57	23,627	No	4	S	Direct
Common Stock	Acquisiton	2017-06-26	9,250	$33.88	32,877	No	4	M	Direct
Common Stock	Disposition	2017-06-26	9,250	$133.57	23,627	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock	Disposition	2017-06-26	9,250	$0.00	9,250	$24.97
Common Stock	Common Stock	Disposition	2017-06-26	9,250	$0.00	9,250	$33.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2017-12-17	No	4	M	Direct
0		2017-09-17	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,800	Indirect	Family Trust

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from $132.86 to $134.35, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The option was fully exercisable.
The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.